Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1001/jamanetworkopen.2021.10782 http://scihub22266oqcxt.onion/10.1001/jamanetworkopen.2021.10782 34061203!8170542!34061203     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       JAMA+Netw+Open 2021 ; 4 (6): e2110782 Nephropedia Template TP {{tp|p=34061203|t=2021. Association of Simulated COVID-19 Vaccination and Nonpharmaceutical Interventions With Infections, Hospitalizations, and Mortality |pdf=|usr=}}{{34061203}} gab.com Text Association of Simulated COVID-19 Vaccination and Nonpharmaceutical Interventions With Infections, Hospitalizations, and Mortality JO: JAMA Netw Open http://www.kidney.de/pget.php?&tw=1&pmid=34061203 #FOAvip IMPORTANCE: Vaccination against SARS-CoV-2 has the potential to significantly reduce transmission and COVID-19 morbidity and mortality. The relative importance of vaccination strategies and nonpharmaceutical interventions (NPIs) is not well understood. OBJECTIVE: To assess the association of simulated COVID-19 vaccine efficacy and coverage scenarios with and without NPIs with infections, hospitalizations, and deaths. DESIGN, SETTING, AND PARTICIPANTS: An established agent-based decision analytical model was used to simulate COVID-19 transmission and progression from March 24, 2020, to September 23, 2021. The model simulated COVID-19 spread in North Carolina, a US state of 10.5 million people. A network of 1?017?720 agents was constructed from US Census data to represent the statewide population. EXPOSURES: Scenarios of vaccine efficacy (50% and 90%), vaccine coverage (25%, 50%, and 75% at the end of a 6-month distribution period), and NPIs (reduced mobility, school closings, and use of face masks) maintained and removed during vaccine distribution. MAIN OUTCOMES AND MEASURES: Risks of infection from the start of vaccine distribution and risk differences comparing scenarios. Outcome means and SDs were calculated across replications. RESULTS: In the worst-case vaccination scenario (50% efficacy, 25% coverage), a mean (SD) of 2?231?134 (117?867) new infections occurred after vaccination began with NPIs removed, and a mean (SD) of 799?949 (60?279) new infections occurred with NPIs maintained during 11 months. In contrast, in the best-case scenario (90% efficacy, 75% coverage), a mean (SD) of 527?409 (40?637) new infections occurred with NPIs removed and a mean (SD) of 450?575 (32?716) new infections occurred with NPIs maintained. With NPIs removed, lower efficacy (50%) and higher coverage (75%) reduced infection risk by a greater magnitude than higher efficacy (90%) and lower coverage (25%) compared with the worst-case scenario (mean [SD] absolute risk reduction, 13% [1%] and 8% [1%], respectively). CONCLUSIONS AND RELEVANCE: Simulation outcomes suggest that removing NPIs while vaccines are distributed may result in substantial increases in infections, hospitalizations, and deaths. Furthermore, as NPIs are removed, higher vaccination coverage with less efficacious vaccines can contribute to a larger reduction in risk of SARS-CoV-2 infection compared with more efficacious vaccines at lower coverage. These findings highlight the need for well-resourced and coordinated efforts to achieve high vaccine coverage and continued adherence to NPIs before many prepandemic activities can be resumed. Twit Text FOAVip Association of Simulated COVID-19 Vaccination and Nonpharmaceutical Interventions With Infections, Hospitalizations, and Mortality ????JAMA Netw Open http://www.kidney.de/pget.php?&tw=1&pmid=34061203 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34061203 #FOAvip English Wikipedia <ref>{{Cite pmid|34061203}}</ref> Association of Simulated COVID-19 Vaccination and Nonpharmaceutical Interventions With Infections, Hospitalizations, and Mortality #MMPMID34061203 Patel MD; Rosenstrom E; Ivy JS; Mayorga ME; Keskinocak P; Boyce RM; Hassmiller Lich K; Smith RL 3rd; Johnson KT; Delamater PL; Swann JL JAMA Netw Open 2021[Jun]; 4 (6): e2110782 PMID34061203show ga IMPORTANCE: Vaccination against SARS-CoV-2 has the potential to significantly reduce transmission and COVID-19 morbidity and mortality. The relative importance of vaccination strategies and nonpharmaceutical interventions (NPIs) is not well understood. OBJECTIVE: To assess the association of simulated COVID-19 vaccine efficacy and coverage scenarios with and without NPIs with infections, hospitalizations, and deaths. DESIGN, SETTING, AND PARTICIPANTS: An established agent-based decision analytical model was used to simulate COVID-19 transmission and progression from March 24, 2020, to September 23, 2021. The model simulated COVID-19 spread in North Carolina, a US state of 10.5 million people. A network of 1?017?720 agents was constructed from US Census data to represent the statewide population. EXPOSURES: Scenarios of vaccine efficacy (50% and 90%), vaccine coverage (25%, 50%, and 75% at the end of a 6-month distribution period), and NPIs (reduced mobility, school closings, and use of face masks) maintained and removed during vaccine distribution. MAIN OUTCOMES AND MEASURES: Risks of infection from the start of vaccine distribution and risk differences comparing scenarios. Outcome means and SDs were calculated across replications. RESULTS: In the worst-case vaccination scenario (50% efficacy, 25% coverage), a mean (SD) of 2?231?134 (117?867) new infections occurred after vaccination began with NPIs removed, and a mean (SD) of 799?949 (60?279) new infections occurred with NPIs maintained during 11 months. In contrast, in the best-case scenario (90% efficacy, 75% coverage), a mean (SD) of 527?409 (40?637) new infections occurred with NPIs removed and a mean (SD) of 450?575 (32?716) new infections occurred with NPIs maintained. With NPIs removed, lower efficacy (50%) and higher coverage (75%) reduced infection risk by a greater magnitude than higher efficacy (90%) and lower coverage (25%) compared with the worst-case scenario (mean [SD] absolute risk reduction, 13% [1%] and 8% [1%], respectively). CONCLUSIONS AND RELEVANCE: Simulation outcomes suggest that removing NPIs while vaccines are distributed may result in substantial increases in infections, hospitalizations, and deaths. Furthermore, as NPIs are removed, higher vaccination coverage with less efficacious vaccines can contribute to a larger reduction in risk of SARS-CoV-2 infection compared with more efficacious vaccines at lower coverage. These findings highlight the need for well-resourced and coordinated efforts to achieve high vaccine coverage and continued adherence to NPIs before many prepandemic activities can be resumed. |*COVID-19/epidemiology/prevention & control/transmission[MESH] |*Communicable Disease Control/methods/organization & administration/statistics & numerical data[MESH] |*Mass Vaccination/organization & administration/statistics & numerical data[MESH] |*Vaccination Coverage/organization & administration/statistics & numerical data[MESH] |Adult[MESH] |COVID-19 Vaccines/*pharmacology[MESH] |Computer Simulation[MESH] |Disease Transmission, Infectious/prevention & control[MESH] |Female[MESH] |Hospitalization/statistics & numerical data[MESH] |Humans[MESH] |Male[MESH] |Mortality[MESH] |North Carolina/epidemiology[MESH] |Risk Assessment/methods/statistics & numerical data[MESH] |SARS-CoV-2[MESH]Association of Simulated COVID-19 Vaccination and Nonpharmaceutical In(epmc).pdf DeepDyve Pubget Overpricing